Retargeting gene delivery using surface-engineered retroviral vector particles

Current Opinion in Biotechnology

Volumn 12, Issue 5, 2001, Pages 461-466

  Lavillette, Dimitri ^a   Russell, Stephen J ^b   Cosset, François Loïc ^a  

^a UNIVERSITÉ DE LYON   (France)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; LIGAND; MEMBRANE PROTEIN; VIRUS VECTOR;

BIOTECHNOLOGY; CELL SPECIFICITY; CELL SURFACE; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; IN VIVO STUDY; NONHUMAN; PLANT GROWTH; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TISSUE SPECIFICITY; TRANSGENE;

RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 0035477273     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(00)00246-9     Document Type: Review

References (53)

1. Retroviral cell targeting vectors
2. Cell targeting by murine retroviral vectors
3. Modifying the host range properties of retroviral vectors
4. Targeting retroviral vectors to CD34-expressing cells: Binding to CD34 does not catalyze virus-cell fusion
5. Retroviral retargeting by envelopes expressing an N-terminal binding domain
6. Identification of the block in targeted retroviral-mediated gene transfer
7. Retrovirus receptors
8. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
9. Definition of a 14-amino-acid peptide essential for the interaction between the murine leukemia virus amphotropic envelope glycoprotein and its receptor
10. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors
11. Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide
12. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system
13. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
14. Retroviral vectors displaying functional antibody fragments
15. Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection
16. A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes
17. Membrane fusion by murine leukemia viruses is activated in cis or in trans by interactions of the receptor-binding domain with a conserved disulfide loop at the carboxy-terminus of the surface glycoproteins
18. Functional interactions between monomers of the retroviral envelope protein complex
19. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library
20. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies
21. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein
22. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in the envelope
23. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
24. Incorporation of tumor vasculature targeting motifs into Moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells
25. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice
26. In vivo cell-type-specific gene delivery with retroviral vectors that display single chain antibodies
27. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopoietic cells
28. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors
29. Retrovirus targeting by tropism restriction to melanoma cells
30. A gene delivery system activatable by disease-associated matrix metalloproteinases
31. A retroviral gene delivery system activatable by plasmin
32. Modification of retroviral tropism by display of IGF-I
33. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
34. Masking of retroviral envelope functions by oligomerizing peptide adaptors
35. In vivo selection of protease cleavage sites from retrovirus display libraries
36. A versatile approach to the targeting of specific cell types by retroviruses
37. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker
38. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein
39. A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor
40. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types
41. Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion
42. Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2
43. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin
44. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses
45. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein
46. Retroviral display of functional binding domains fused to the amino-terminus of influenza haemagglutinin
47. Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: Separation of attachment and fusion functions on different molecules
48. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors
49. Efficient transduction of primary primate PBLs with SIV-derived lentiviral vectors pseudotyped with a cytoplasmic tail-modified glycoprotein derived from RD114
50. Antibody-directed targeting of retroviral vectors via cell surface antigens
51. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction
52. Evidence for non-specific adsorption of targeted retrovirus vector particles to cells
53. The plasma membrane as a combat zone in the HIV battlefield